Price
$120.56+1.72%Social Signal Score
Analyst Ratings
44 analystsRevenue
$1.67B+521.24%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- William J. Meury
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,844
- Beta
- 0.77
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 11.67
Financials
Revenue
$1.67B+521.2%Net Income
$585.61M+1488.0%EBITDA
$752.10M+1061.9%Free Cash Flow
$495.25M+529.8%EPS (diluted)
$2.81+1378.9%Shares Outstanding (diluted)
208.22M+7.2%Operating Expenses
$868.68MCash & Debt
$4.54BReturn of Capital
$0.00Revenue by Segment (annual)
$4.98BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.14B | $1.29B | $6.59 |
| 2024 | $4.24B | $32.62M | $0.16 |
| 2023 | $3.70B | $597.60M | $2.67 |
| 2022 | $3.39B | $340.66M | $1.53 |
| 2021 | $2.99B | $948.58M | $4.30 |
| 2020 | $2.67B | $-295.70M | $-1.36 |
| 2019 | $2.16B | $446.91M | $2.08 |
| 2018 | $1.88B | $109.49M | $0.52 |
| 2017 | $1.54B | $-313.14M | $-1.53 |
| 2016 | $1.11B | $104.22M | $0.55 |
| 2015 | $753.75M | $6.53M | $0.04 |
| 2014 | $511.50M | $-48.48M | $-0.29 |
| 2013 | $354.95M | $-83.15M | $-0.56 |
| 2012 | $297.06M | $-44.32M | $-0.34 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $9.68
- Implied price
- $145.27
- Return from $115.30
- 4.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $72.23 — -37.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| -2.0% | -10.7% | -7.6% | -5.0% | -2.6% | -0.4% |
| 3.0% | -6.1% | -2.9% | -0.1% | 2.4% | 4.7% |
| 8.0% | -1.6% | 1.8% | 4.7% | 7.4% | 9.8% |
| 13.0% | 3.0% | 6.5% | 9.6% | 12.4% | 14.9% |
| 18.0% | 7.5% | 11.2% | 14.4% | 17.3% | 20.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (19)
- Newszacks.com·5d ago·Neutral
INCY or TECH: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?
View source ↗ - News (RSS)seekingalpha·9d ago·Neutral
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder
View source ↗ - Newsbusinesswire.com·10d ago·Neutral
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva.
View source ↗ - News (RSS)investing·15d ago·Neutral
Specialised Therapeutics expands Incyte partnership to Australia
View source ↗ - Newsmarketbeat.com·16d ago·Negative
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·21d ago·Positive
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold? Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (Marketaux)seekingalpha.com·28d ago·Positive
Incyte: Solid Strategies For Continued Growth, But A Possible Pullback Looms (NASDAQ:INCY) Incyte: Solid Strategies For Continued Growth, But A Possible Pullback Looms (NASDAQ:INCY)
View source ↗ - News (RSS)seekingalpha·34d ago·Negative
Incyte Corporation: Why Jakafi Is No Longer The Real Story Here
View source ↗ - Newsseekingalpha.com·34d ago·Neutral
…e assets. 2Q26 results showed 17% underlying net sales growth, broad-based portfolio expansion, and strong operating leverage despite one-time Opzelura CMS benefits. INCY's pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are pivotal for validating its multi-engine growth thesis.
View source ↗ - News (Marketaux)gurufocus.com·35d ago·Positive
Incyte (INCY) Enters Agreement With CMS to Improve Medicaid Access to Jakafi Incyte Corporation INC[+245 characters]
View source ↗ - News (RSS)yahoo·38d ago·Neutral
Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?
View source ↗ - Newszacks.com·39d ago·Neutral
Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue? Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)yahoo·48d ago·Neutral
Incyte Stock: Is Wall Street Bullish or Bearish?
View source ↗ - News (RSS)yahoo·54d ago·Positive
Incyte Sales Growth Drives Share Price Gains
View source ↗ - Newsfxempire.com·54d ago·Positive
Incyte Sales Growth Drives Share Price Gains Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 2026.
View source ↗ - Newsbusinesswire.com·59d ago·Neutral
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
View source ↗
Earnings
Tue, Oct 27(in 3 weeks)
Consensus estimate $-3.16 per share
Typical surprise +14.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$3.09 vs $2.15beat
- Tue, Apr 28$1.81 vs $1.34beat
- Tue, Feb 10$1.80 vs $1.90miss
- Tue, Oct 28$2.26 vs $1.66beat
- Tue, Jul 29$1.57 vs $1.39beat
- Tue, Apr 29$1.16 vs $1.01beat
Estimates and results for INCY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INCY officers and directors.
- Bought
- —
- Sold
- $15.0m
0 trades
21 trades
- Cagnoni Pablo Jsold
- Cagnoni Pablo Jsold
- Cagnoni Pablo Jsold
- Cagnoni Pablo Jsold
- Cagnoni Pablo Jsold
- Mayes Patrick Asold
- Mayes Patrick Asold
- Cagnoni Pablo Jsold
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (11d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 6, 2023 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (12d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (15d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 7, 2023 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 11, 2021 (20d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Oct 14, 2020 (28d later)Buy$1,001 - $15,000
- Shelley Moore Capitosenate · WV · disclosed Dec 8, 2018 (26d later)Sell$1,001 - $15,000
- Shelley Moore Capitosenate · WV · disclosed Oct 6, 2017 (28d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.